Literature DB >> 20095791

Antioxidant and mitochondrial protective effects of oxidized metabolites of oltipraz.

Song Hwa Choi1, Young Mi Kim, Jung Min Lee, Sang Geon Kim.   

Abstract

IMPORTANCE OF THE FIELD: Comprehensive studies indicate that oltipraz exerts cancer chemopreventive effects. Oltipraz has other therapeutic potentials, which include anti-fibrotic effect, inhibition of insulin resistance, mitochondrial protection and cytoprotective effect against oxidative stress. Although antioxidant mechanisms may account for its cancer chemopreventive effect, details on the molecular mechanism still remain to be clarified. AREAS COVERED IN THIS REVIEW: Two major metabolic pathways of oltipraz include oxidative desulfuration of the thione to yield 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiol-3-one and molecular rearrangement to 7-methyl-6,8-bis(methylthio)H-pyrrolo[1,2-a]pyrazine. In addition to the diverse pharmacological effects of oltipraz, the oxidized metabolites may have distinct biological effects on cell survival. The AMP-activated protein kinase pathway has been recognized as a key cascade for mitochondrial protection and cell survival events, which can be activated by the oxidized metabolites of oltipraz. WHAT THE READER WILL GAIN: In this review, the metabolic activation of oltipraz and the role of the cell signaling pathways in regulating the expression of Phase II genes and antioxidant activity are discussed with particular reference to their effects on mitochondrial protection and cell survival. TAKE HOME MESSAGE: In terms of therapeutic potential, the findings reviewed here demonstrate a therapeutic potential for oxidized metabolite of oltipraz and offer comparison of antioxidant capacity between metabolites and parent compound.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20095791     DOI: 10.1517/17425250903427972

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  8 in total

1.  Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice.

Authors:  Z Yu; W Shao; Y Chiang; W Foltz; Z Zhang; W Ling; I G Fantus; T Jin
Journal:  Diabetologia       Date:  2010-12-16       Impact factor: 10.122

Review 2.  Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad.

Authors:  Angelo Sparaneo; Federico Pio Fabrizio; Lucia Anna Muscarella
Journal:  Oxid Med Cell Longev       Date:  2016-10-25       Impact factor: 6.543

Review 3.  Emerging roles of Nrf2 signal in non-small cell lung cancer.

Authors:  Yijun Tian; Qian Liu; Xuelian He; Xun Yuan; Yuan Chen; Qian Chu; Kongming Wu
Journal:  J Hematol Oncol       Date:  2016-02-27       Impact factor: 17.388

4.  Oltipraz Prevents High Glucose-Induced Oxidative Stress and Apoptosis in RSC96 Cells through the Nrf2/NQO1 Signalling Pathway.

Authors:  Zengxin Jiang; Mengxuan Bian; Jingping Wu; Defang Li; Lei Ding; Qingmin Zeng
Journal:  Biomed Res Int       Date:  2020-06-23       Impact factor: 3.411

5.  Cartilage targeting therapy with reactive oxygen species-responsive nanocarrier for osteoarthritis.

Authors:  Zengxin Jiang; Hao Wang; Zeng Zhang; Jianfeng Pan; Hengfeng Yuan
Journal:  J Nanobiotechnology       Date:  2022-09-19       Impact factor: 9.429

Review 6.  An update of Nrf2 activators and inhibitors in cancer prevention/promotion.

Authors:  Farhad Pouremamali; Amir Pouremamali; Mehdi Dadashpour; Narges Soozangar; Farhad Jeddi
Journal:  Cell Commun Signal       Date:  2022-06-30       Impact factor: 7.525

7.  Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain.

Authors:  Ya-Qun Zhou; Dai-Qiang Liu; Shu-Ping Chen; Nan Chen; Jia Sun; Xiao-Mei Wang; Fei Cao; Yu-Ke Tian; Da-Wei Ye
Journal:  Acta Pharmacol Sin       Date:  2020-03-19       Impact factor: 6.150

8.  Effects of C2-Ceramide and Oltipraz on Hepatocyte Nuclear Factor-1 and Glutathione S-Transferase A1 in Acetaminophen-Mediated Acute Mice Liver Injury.

Authors:  Xin Ma; Yicong Chang; Yuanyuan Zhang; Ishfaq Muhammad; Chenxi Shi; Rui Li; Changwen Li; Zhi Li; Yuexia Lin; Qing Han; Fangping Liu
Journal:  Front Pharmacol       Date:  2018-09-11       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.